Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2018-08-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/sacubitril-valsartan-evaluation-of-safety-and-efficacy-as-an-antihypertensive-treatment |
| _version_ | 1819073174772383744 |
|---|---|
| author | Sarah L Anderson Joel C Marrs |
| author_facet | Sarah L Anderson Joel C Marrs |
| author_sort | Sarah L Anderson |
| collection | DOAJ |
| description | Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-inclass angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction. During clinical trials for heart failure as well as in independent trials for HTN, sacubitril/valsartan has demonstrated safety and efficacy when it comes to BP lowering, making it a promising antihypertensive agent. Most trials of sacubitril/valsartan were 8 to 12 weeks in length and demonstrated a clinically relevant BP lowering that was frequently more significant than its comparators. While more data are needed to confirm its role as an antihypertensive agent, the data available are promising and it is anticipated that sacubitril/valsartan will gain an indication of HTN. |
| first_indexed | 2024-12-21T17:49:26Z |
| format | Article |
| id | doaj.art-f73218bfaa384a5fb036163edbc1edd0 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 1740-4398 |
| language | English |
| last_indexed | 2024-12-21T17:49:26Z |
| publishDate | 2018-08-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-f73218bfaa384a5fb036163edbc1edd02022-12-21T18:55:24ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982018-08-0171710.7573/dic.212542Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatmentSarah L AndersonJoel C Marrs Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-inclass angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction. During clinical trials for heart failure as well as in independent trials for HTN, sacubitril/valsartan has demonstrated safety and efficacy when it comes to BP lowering, making it a promising antihypertensive agent. Most trials of sacubitril/valsartan were 8 to 12 weeks in length and demonstrated a clinically relevant BP lowering that was frequently more significant than its comparators. While more data are needed to confirm its role as an antihypertensive agent, the data available are promising and it is anticipated that sacubitril/valsartan will gain an indication of HTN.https://www.drugsincontext.com/sacubitril-valsartan-evaluation-of-safety-and-efficacy-as-an-antihypertensive-treatmentangiotensin receptor blockershypertensionneprilysin inhibitor |
| spellingShingle | Sarah L Anderson Joel C Marrs Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment Drugs in Context angiotensin receptor blockers hypertension neprilysin inhibitor |
| title | Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment |
| title_full | Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment |
| title_fullStr | Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment |
| title_full_unstemmed | Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment |
| title_short | Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment |
| title_sort | sacubitril valsartan evaluation of safety and efficacy as an antihypertensive treatment |
| topic | angiotensin receptor blockers hypertension neprilysin inhibitor |
| url | https://www.drugsincontext.com/sacubitril-valsartan-evaluation-of-safety-and-efficacy-as-an-antihypertensive-treatment |
| work_keys_str_mv | AT sarahlanderson sacubitrilvalsartanevaluationofsafetyandefficacyasanantihypertensivetreatment AT joelcmarrs sacubitrilvalsartanevaluationofsafetyandefficacyasanantihypertensivetreatment |